• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series

    2/6/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DNA alert in real time by email

    Evolution of Ferment conference to kick off Summer 2025

    BOSTON, Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of its flagship annual conference dedicated to advancing Ginkgo's mission of making biology easier to engineer. Throughout 2025, Ginkgo product teams will hold a series of focused Ferments at Ginkgo's beautiful event venue, located at 19 Fid Kennedy Ave in Boston's historic Seaport District, just a five-minute walk from Ginkgo's headquarters.

    Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series

    Each Ferment in the 2025 series will dive deep into specific focus areas—spanning Ginkgo's cell engineering and biosecurity offerings—and highlight how Ginkgo's broad horizontal platform for engineering biology is enabling transformative solutions across markets including pharma & biotech, agriculture, industrial biotech, government, and beyond. Speawkers and panelists will include Ginkgo experts, partners, and industry leaders who are applying engineered biology to discover, optimize, and manufacture cutting-edge products.

    Attendees will also get a close look at Ginkgo's technologies and the innovations they have delivered to partners around the world. In addition, entirely new products and next-generation services will be showcased, including Ginkgo Datapoints' high-throughput AI-driven data generation services; Ginkgo Automation's Reconfigurable Automation Cart (RAC) systems; and Ginkgo Biosecurity's product suite anchored by Canopy (persistent, environmental pathogen monitoring) and Horizon (data-driven global threat intelligence).

    "We made big changes in 2024, and our mission is stronger than ever," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "Whether you're seeking the perfect antibody, looking to spin up a data generation engine to train your biological AI model, outfitting your lab with extensible and flexible automation, or building a new biosecurity solution to meet your mission's demands, you can find your needle in our tech stack. We're excited to show how the platform is evolving, and our new automation capabilities, expanded AI offerings, and next-gen data services will all be on full display at our 2025 Ferment event series. Join us as we celebrate the transformative power of biology and the foundational advancements being made by pioneers across our industry."

    A larger, platform-wide Ferment will return in 2026, alternating years with targeted business-specific gatherings.

    2025 Ferment Series Calendar

    • Summer: Datapoints x AI

      Ginkgo Datapoints generates high-quality data at the scale, price, and speed you need. Learn more about our new data-generation services (Functional Genomics & Antibody Developability) and dive into the AI models that we're deploying and leveraging to accelerate biotech R&D.
    • September: Ginkgo Biopharma Solutions

      Ginkgo Biopharma Solutions partners to accelerate your preclinical drug discovery and development research with cutting-edge automation, AI-driven tools, and world-class scientific expertise. Our solutions and products streamline research, enhance efficiency, and empower drug developers to push the boundaries of innovation. Join us to explore our latest offerings and see how our teams help bring therapeutics from concept to clinic.
    • October: Biosecurity

      Exploring the future of biosecurity. Experts from government and industry will discuss strategies for identifying, monitoring, and mitigating biological risks.
    • November: Automation

      Demonstrations of Ginkgo's RAC Automation systems, plus in-depth tours of the Foundry to illustrate how large-scale data generation and new automation tech are fueling breakthroughs in cell programming.

    Dates are subject to change.

    Ginkgo's Agriculture team is especially excited to meet with partners, old and new, at World AgriTech in San Francisco (March) and ABIM (October), in addition to other industry conferences. As a Gold Sponsor of World AgriTech SF, Ginkgo will be hosting a tour of its R&D facility in West Sacramento, CA on March 10, 2025. Find out more about that pre-summit tour here.

    Connect with fellow innovators and leaders, and develop the relationships and ideas that will shape the future of biotechnology. For more information about Ginkgo's 2025 Ferment series and to subscribe to updates, please visit our series home page, 

    About Ginkgo Bioworks:

    Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

    GINKGO BIOWORKS INVESTOR CONTACT:

    [email protected]

    GINKGO BIOWORKS MEDIA CONTACT:

    [email protected]

    Forward-Looking Statements of Ginkgo Bioworks

    This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo's cell engineering and biosecurity offerings. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) the outcome of any pending or potential legal proceedings against Ginkgo, (vii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (viii) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (ix) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 29, 2024, Ginkgo's most recent quarterly report on Form 10-Q, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

    (PRNewsfoto/Ginkgo Bioworks)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-to-host-6th-annual-ferment-as-boston-based-conference-series-302370156.html

    SOURCE Ginkgo Bioworks

    Get the next $DNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNA

    DatePrice TargetRatingAnalyst
    5/15/2024Neutral → Sell
    BTIG Research
    5/10/2024Mkt Perform → Underperform
    William Blair
    11/14/2023$3.50 → $2.50Outperform → Mkt Perform
    Raymond James
    11/9/2023Buy → Neutral
    BTIG Research
    6/2/2023$3.00 → $1.25Neutral → Sell
    Goldman
    5/11/2023Outperform → Mkt Perform
    William Blair
    11/29/2022$6.00Buy
    Berenberg
    10/4/2022$5.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $DNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation

    Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.To ask a

    2/19/26 8:00:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products

    Collaboration aims to develop a commercialization-ready microorganism to manufacture next-generation peptide crop solutions at grower-friendly costsBOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA, ", Ginkgo", )) and Invaio Sciences, an agricultural biotechnology company leading in nature-positive crop protection solutions, today announced a collaboration to develop strains that can efficiently manufacture peptide-based crop protection inputs. Growers are seeking inputs that protect agricultural crops from pests that are increasingly resistant to conventional chem

    2/18/26 8:00:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark

    Research conducted in collaboration with OpenAI using Ginkgo's cloud laboratoryPreprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesisGPT-5-driven autonomous lab executed over 36,000 experimentsGinkgo now selling the AI-improved reaction mix in its reagents store, showing commercial potential of AI-driven scienceBOSTON, Feb. 5, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously designed, executed, and learned from biological experiments with minimal human involvement. In a new preprint, the company reports the system reduced cell-free p

    2/5/26 2:00:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sankar Shyam bought $514,750 worth of shares (625,000 units at $0.82), increasing direct ownership by 36% to 2,356,874 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    5/16/24 5:08:50 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sloan Harry bought $271,815 worth of shares (297,619 units at $0.91), increasing direct ownership by 71% to 718,540 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    5/14/24 5:16:23 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Coen Steven P. converted options into 1,805 shares and sold $8,667 worth of shares (972 units at $8.92), increasing direct ownership by 11% to 8,321 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    1/22/26 4:12:16 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Coen Steven P. converted options into 1,486 shares and sold $6,540 worth of shares (736 units at $8.89), increasing direct ownership by 11% to 7,488 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    12/16/25 5:11:04 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Coen Steven P. converted options into 2,547 shares and sold $17,907 worth of shares (1,312 units at $13.65), increasing direct ownership by 22% to 6,738 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    10/21/25 4:56:24 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SCHEDULE 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    2/5/26 10:10:09 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Leadership Update, Other Events

    8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    12/23/25 5:26:04 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SCHEDULE 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/14/25 4:16:07 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Leadership Updates

    Live Leadership Updates

    View All

    Merlin Appoints Ryan Carrithers as Chief Financial Officer, Increasing Public Market Readiness

    Carrithers brings to Merlin a unique blend of technical expertise, capital markets experience, and operational rigor, backed by a proven record in scaling innovative automation and aerospace companies Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a pivotal moment as the company prepares to go public in a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). In this role, he will oversee all of Merlin's financial operations and strategy, investor relations, M&A or strategic partnerships that support its autonomy road

    11/4/25 9:00:00 AM ET
    $ASTR
    $BACQ
    $DNA
    Transportation Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

    Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs. BOSTON, Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O'Sullivan as Head of Commercial for Ginkgo Automation. Brian joins Ginkgo Automation from HighRes Biosolutions, where he led their commercial efforts. In his new role, Brian wi

    8/12/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ginkgo Bioworks downgraded by BTIG Research

    BTIG Research downgraded Ginkgo Bioworks from Neutral to Sell

    5/15/24 7:33:13 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks downgraded by William Blair

    William Blair downgraded Ginkgo Bioworks from Mkt Perform to Underperform

    5/10/24 7:33:29 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks downgraded by Raymond James with a new price target

    Raymond James downgraded Ginkgo Bioworks from Outperform to Mkt Perform and set a new price target of $2.50 from $3.50 previously

    11/14/23 9:04:22 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Financials

    Live finance-specific insights

    View All

    Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation

    Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.To ask a

    2/19/26 8:00:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Reports Third Quarter 2025 Financial Results

    Ginkgo provides an update on its third quarter financial results BOSTON, Nov. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced its results for the third quarter ended September 30, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Third Quarter 2025 Financial Results Third quarter 2025 Total revenue of $39 million compared to $89 million in the comparable prior year period, a decrea

    11/6/25 4:05:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Announces Date of Third Quarter 2025 Results Presentation

    Presentation and Q&A session scheduled for post-market on Thursday, November 6, 2025 BOSTON, Oct. 30, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available. To ask a question ah

    10/30/25 4:05:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/14/24 4:31:49 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/12/24 3:58:52 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/4/24 11:56:06 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care